U.S. markets close in 4 hours 4 minutes
  • S&P 500

    4,218.57
    +52.12 (+1.25%)
     
  • Dow 30

    33,806.49
    +516.41 (+1.55%)
     
  • Nasdaq

    14,123.46
    +93.09 (+0.66%)
     
  • Russell 2000

    2,279.11
    +41.37 (+1.85%)
     
  • Crude Oil

    73.12
    +1.48 (+2.07%)
     
  • Gold

    1,785.40
    +16.40 (+0.93%)
     
  • Silver

    26.07
    +0.10 (+0.37%)
     
  • EUR/USD

    1.1916
    +0.0051 (+0.43%)
     
  • 10-Yr Bond

    1.4730
    +0.0230 (+1.59%)
     
  • GBP/USD

    1.3918
    +0.0109 (+0.79%)
     
  • USD/JPY

    110.2250
    +0.0750 (+0.07%)
     
  • BTC-USD

    32,623.80
    -1,823.23 (-5.29%)
     
  • CMC Crypto 200

    798.79
    -51.56 (-6.06%)
     
  • FTSE 100

    7,062.29
    +44.82 (+0.64%)
     
  • Nikkei 225

    28,010.93
    -953.15 (-3.29%)
     

Why Earnings Season Could Be Great for Aldeyra Therapeutics (ALDX)

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Investors are always looking for stocks that are poised to beat at earnings season and Aldeyra Therapeutics, Inc. ALDX may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Aldeyra Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ALDX in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 25 cents per share for ALDX, narrower than the broader Zacks Consensus Estimate of a loss of 26 cents per share. This suggests that analysts have very recently bumped up their estimates for ALDX, giving the stock a Zacks Earnings ESP of +2.60% heading into earnings season.

Aldeyra Therapeutics, Inc. Price and EPS Surprise

Aldeyra Therapeutics, Inc. Price and EPS Surprise
Aldeyra Therapeutics, Inc. Price and EPS Surprise

Aldeyra Therapeutics, Inc. price-eps-surprise | Aldeyra Therapeutics, Inc. Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that ALDX has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Aldeyra Therapeutics, and that a beat might be in the cards for the upcoming report.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Aldeyra Therapeutics, Inc. (ALDX) : Free Stock Analysis Report

To read this article on Zacks.com click here.